labetalol has been researched along with Coronary Heart Disease in 45 studies
Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.
labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.
2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The systemic and coronary hemodynamic effects of combined alpha- and beta-adrenergic blockade produced by oral labetalol were assessed in 12 normotensive patients with angina pectoris and an ischemic electrocardiographic response to exercise stress." | 7.67 | Systemic and coronary hemodynamic effects of combined oral alpha- and beta-adrenergic blockade (labetalol) in normotensive patients with stable angina pectoris and positive exercise stress tests. ( Feldman, RL; Hill, JA; Prida, XE, 1988) |
| "Labetalol was followed by significant dose related decreases in systemic blood pressure and vascular resistance associated with a significant increase in cardiac output; heart rate and pulmonary artery occluded pressure were unchanged." | 6.65 | Comparative haemodynamic dose response effects of propranolol and labetalol in coronary heart disease. ( Ahuja, RC; Nelson, GI; Silke, B; Taylor, SH, 1982) |
| "Labetalol is an adrenoceptor blocking drug with combined alpha- and beta-blocking properties." | 6.38 | Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease. ( Benfield, P; Goa, KL; Sorkin, EM, 1989) |
| "This is the first reported large clinical trial of the antianginal and acute ischemic effectiveness and safety of dilevalol (the R, R-isomer of labetalol) in patients with chronic stable angina pectoris." | 5.06 | The efficacy and safety of dilevalol in patients with chronic stable angina pectoris. ( Bennett, WT; Bittar, N; Glasser, SP; Kinhal, V; Koehn, DK, 1989) |
| "The bicycle exercise tolerance was studied in ten patients with angina pectoris after one week's treatment with an alpha-beta-blocker (labetalol 300 mg b." | 5.05 | Relation between ST-depression and chest pain in patients with coronary heart disease receiving no treatment and after beta-blockade and combined alpha-beta-blockade. ( Bjurö, T; Hagman, M; Nyberg, G; Smith, U, 1981) |
| "The systemic and coronary hemodynamic effects of combined alpha- and beta-adrenergic blockade produced by oral labetalol were assessed in 12 normotensive patients with angina pectoris and an ischemic electrocardiographic response to exercise stress." | 3.67 | Systemic and coronary hemodynamic effects of combined oral alpha- and beta-adrenergic blockade (labetalol) in normotensive patients with stable angina pectoris and positive exercise stress tests. ( Feldman, RL; Hill, JA; Prida, XE, 1988) |
| "More metoprolol-treated patients withdrew because of depression (6 vs less than 1%; p = 0." | 2.66 | Influence of beta 2 agonism and beta 1 and beta 2 antagonism on adverse effects and plasma lipoproteins: results of a multicenter comparison of dilevalol and metoprolol. ( Ahmad, S; Glasser, SP; Lucas, C; Lutz, LJ; Materson, BJ; Morledge, JH; Ramanathan, KB; Saunders, E; Schnaper, HW; Vlachakis, ND, 1989) |
| "Labetalol pretreatment appears satisfactory and may be useful in patients with coronary artery disease who have a normal left ventricular ejection fraction." | 2.66 | Circulatory responses to thiopentone and tracheal intubation in patients with coronary artery disease. Effects of pretreatment with labetalol. ( Brodaty, D; Dubois, C; Fischler, M; Guilmet, D; Melchior, JC; Schlumberger, S; Vourc'h, G, 1985) |
| "To test the hypothesis that the depression of cardiac performance induced by competitive blockade of sympathetic stimulation at beta-adrenoceptors could be attenuated by the addition of a high level of intrinsic sympathomimetic activity (ISA) or concomitant alpha- and beta-blockade, the haemodynamic dose-response effects of propranolol (non-cardioselective, no ISA), pindolol (non-cardioselective, high ISA) and labetalol (non-cardioselective, alpha-blocker) were compared in a randomized study of 30 patients with stable coronary artery disease." | 2.65 | Beta-blockade in ischaemic heart disease--influence of concomitant ISA or alpha-blockade on haemodynamic profile. ( Ahuja, RC; Nelson, GI; Silke, B; Taylor, SH, 1983) |
| "Labetalol was followed by significant dose related decreases in systemic blood pressure and vascular resistance associated with a significant increase in cardiac output; heart rate and pulmonary artery occluded pressure were unchanged." | 2.65 | Comparative haemodynamic dose response effects of propranolol and labetalol in coronary heart disease. ( Ahuja, RC; Nelson, GI; Silke, B; Taylor, SH, 1982) |
| "Labetalol is an adrenoceptor blocking drug with combined alpha- and beta-blocking properties." | 2.38 | Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease. ( Benfield, P; Goa, KL; Sorkin, EM, 1989) |
| "Labetalol is a unique antihypertensive agent which is a competitive peripheral antagonist at both alpha- and beta-adrenoceptor sites." | 2.37 | Current status of labetalol, the first alpha- and beta-blocking agent. ( Kanto, JH, 1985) |
| "Labetalol appears to be a useful drug for treating the hypertensive heart and its many complications." | 2.37 | Properties of labetalol, a combined alpha- and beta-blocking agent, relevant to the treatment of myocardial ischemia. ( Frishman, WH, 1988) |
| "Labetalol were evaluated in 9 CAD patients during a surgical procedure for myocardial revascularisation." | 1.27 | I.V. Labetalol during coronary artery surgery. ( Joucken, K, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 39 (86.67) | 18.7374 |
| 1990's | 5 (11.11) | 18.2507 |
| 2000's | 1 (2.22) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chiddo, A | 1 |
| Mastrangelo, D | 1 |
| Gaglione, A | 1 |
| Boscia, F | 1 |
| Quagliara, D | 1 |
| Franchini, G | 1 |
| Rizzon, P | 1 |
| Johns, VJ | 1 |
| Taylor, SH | 4 |
| Silke, B | 3 |
| Nelson, GI | 3 |
| Ahuja, RC | 3 |
| Ram, CV | 2 |
| Fagard, R | 1 |
| Reybrouck, T | 1 |
| Vanhees, L | 1 |
| Cattaert, A | 1 |
| Vanmeenen, T | 1 |
| Grauwels, R | 1 |
| Amery, A | 1 |
| Mulac, KD | 1 |
| Meryn, S | 1 |
| Okoli, RC | 1 |
| Lubbe, WF | 1 |
| Nguyen, T | 1 |
| Edwards, MF | 1 |
| Joucken, K | 1 |
| Krug, H | 1 |
| Poprawski, K | 1 |
| Ochotny, R | 1 |
| Nyberg, G | 1 |
| Bjurö, T | 1 |
| Hagman, M | 1 |
| Smith, U | 1 |
| Gagnon, RM | 1 |
| Morissette, M | 1 |
| Présant, S | 1 |
| Savard, D | 1 |
| Lemire, J | 1 |
| Condorelli, M | 1 |
| Brevetti, G | 1 |
| Chiariello, M | 1 |
| Miceli, D | 1 |
| Lavecchia, G | 1 |
| Paudice, G | 1 |
| Verrienti, S | 1 |
| Robertson, JI | 1 |
| Pogwizd, SM | 1 |
| Sharma, AD | 1 |
| Corr, PB | 1 |
| Farhat, F | 1 |
| Loisance, D | 1 |
| Garnier, JP | 1 |
| Kirsch, M | 1 |
| Frishman, W | 1 |
| Halprin, S | 1 |
| Koch, G | 4 |
| Fransson, L | 3 |
| den Boer, MO | 1 |
| Sassen, LM | 1 |
| van der Giessen, WJ | 1 |
| Saxena, PR | 1 |
| Verdouw, PD | 1 |
| Strein, K | 1 |
| Sponer, G | 1 |
| Prichard, BN | 1 |
| Messerli, FH | 1 |
| Materson, BJ | 1 |
| Vlachakis, ND | 1 |
| Glasser, SP | 2 |
| Lucas, C | 1 |
| Ramanathan, KB | 1 |
| Ahmad, S | 1 |
| Morledge, JH | 1 |
| Saunders, E | 1 |
| Lutz, LJ | 1 |
| Schnaper, HW | 1 |
| Bittar, N | 1 |
| Kinhal, V | 1 |
| Bennett, WT | 1 |
| Koehn, DK | 1 |
| Higgins, TL | 1 |
| Estafanous, FG | 1 |
| Goa, KL | 1 |
| Benfield, P | 1 |
| Sorkin, EM | 1 |
| Haehn, KD | 1 |
| Hotan, W | 1 |
| Moerchel, J | 1 |
| Müller, J | 1 |
| Berdeaux, A | 1 |
| Bonhenry, C | 1 |
| Giudicelli, JF | 1 |
| Lepäntalo, M | 1 |
| Kanto, JH | 1 |
| Adamska-Dyniewska, H | 1 |
| Dziekański, S | 1 |
| Pruszczyński, J | 1 |
| Stone, JG | 1 |
| Foëx, P | 1 |
| Sear, JW | 1 |
| Johnson, LL | 1 |
| Khambatta, HJ | 1 |
| Triner, L | 1 |
| Frishman, WH | 1 |
| Feldman, RL | 2 |
| Prida, XE | 2 |
| Lambert, CR | 1 |
| Hill, JA | 2 |
| Glogar, DH | 1 |
| Fischler, M | 1 |
| Dubois, C | 1 |
| Brodaty, D | 1 |
| Schlumberger, S | 1 |
| Melchior, JC | 1 |
| Guilmet, D | 1 |
| Vourc'h, G | 1 |
| Meese, RB | 1 |
| Ourbak, P | 1 |
| Lardoux, H | 1 |
| Pornin, M | 1 |
| Bouziri, S | 1 |
| Allal, J | 1 |
| Duong, TC | 1 |
| Sellier, P | 1 |
| Maurice, M | 1 |
10 reviews available for labetalol and Coronary Heart Disease
| Article | Year |
|---|---|
Beta-blocking drugs for arrhythmias, hypertension, and ischemic heart disease.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Animals; Arrhythmias, Cardiac; Atenolol; Blood Pressur | 1984 |
Alpha- and beta-blockade in angina pectoris.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angina Pectoris; Blood Platelets; Carbohy | 1984 |
Hypertensive crisis.
Topics: Antihypertensive Agents; Brain Diseases; Cerebrovascular Disorders; Clonidine; Coronary Disease; Dia | 1984 |
Experimental and clinical pharmacology of carvedilol and other drugs combining vasodilation and beta-adrenoceptor antagonism in a single molecule.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Celiprolol; Coronary Disease; Heart Fa | 1990 |
Pharmacological and clinical aspects of drug therapy in coronary heart disease: clinical aspects of therapy with beta-adrenoceptor antagonists.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Coronary Disease; Hemodynamics; Humans | 1990 |
Hemodynamic and cardiac adaptation in essential hypertension. Consequences for therapy.
Topics: Adaptation, Physiological; Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aging; Black People | 1985 |
Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease.
Topics: Coronary Disease; Humans; Hypertension; Labetalol | 1989 |
Current status of labetalol, the first alpha- and beta-blocking agent.
Topics: Adrenal Gland Neoplasms; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Anesthesia; Biot | 1985 |
Properties of labetalol, a combined alpha- and beta-blocking agent, relevant to the treatment of myocardial ischemia.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Coronary Disease; Humans; Labetalol | 1988 |
Hypertensive cardiovascular emergencies.
Topics: Antihypertensive Agents; Brain Diseases; Cerebrovascular Disorders; Clonidine; Coronary Disease; Dia | 1985 |
15 trials available for labetalol and Coronary Heart Disease
| Article | Year |
|---|---|
Beta-blockade in ischaemic heart disease--influence of concomitant ISA or alpha-blockade on haemodynamic profile.
Topics: Adult; Clinical Trials as Topic; Coronary Disease; Dose-Response Relationship, Drug; Ethanolamines; | 1983 |
Haemodynamic advantages of combined alpha-blockade and beta-blockade over beta-blockade alone in patients with coronary heart disease.
Topics: Adult; Blood Pressure; Cardiac Output; Coronary Disease; Ethanolamines; Hemodynamics; Humans; Labeta | 1982 |
Relation between ST-depression and chest pain in patients with coronary heart disease receiving no treatment and after beta-blockade and combined alpha-beta-blockade.
Topics: Aged; Angina Pectoris; Blood Pressure; Coronary Disease; Electrocardiography; Ethanolamines; Exercis | 1981 |
Effects of combined alpha- and beta-blockade by labetalol in patients with coronary artery disease.
Topics: Adult; Aged; Blood Pressure; Cardiac Output; Coronary Disease; Electrocardiography; Ethanolamines; E | 1982 |
Comparative haemodynamic dose response effects of propranolol and labetalol in coronary heart disease.
Topics: Adult; Coronary Disease; Dose-Response Relationship, Drug; Ethanolamines; Heart Ventricles; Hemodyna | 1982 |
Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 7. New horizons in beta-adrenoceptor blockade therapy: labetalol.
Topics: Arrhythmias, Cardiac; Chemical Phenomena; Chemistry; Clinical Trials as Topic; Coronary Disease; Eth | 1979 |
Hemodynamic effects at rest and during exercise of combined alpha/beta-receptor blockade and of beta-receptor blockade alone in patients with ischemic heart disease.
Topics: Coronary Disease; Hemodynamics; Humans; Labetalol; Male; Metoprolol; Middle Aged; Physical Exertion; | 1987 |
Influence of beta 2 agonism and beta 1 and beta 2 antagonism on adverse effects and plasma lipoproteins: results of a multicenter comparison of dilevalol and metoprolol.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Aged; Cholesterol; Coronary Disease; Double-B | 1989 |
The efficacy and safety of dilevalol in patients with chronic stable angina pectoris.
Topics: Adrenergic beta-Antagonists; Adult; Angina Pectoris; Chronic Disease; Coronary Disease; Double-Blind | 1989 |
Hemodynamic and adrenergic effects of combined alpha/beta-receptor blockade versus combined beta-receptor and slow channel calcium blockade in patients with ischemic heart disease.
Topics: Adult; Aged; Blood Pressure; Coronary Disease; Drug Therapy, Combination; Exercise Test; Hemodynamic | 1989 |
[Combined alpha and beta blockade with labetalol. Multicenter general practice study in hypertensive patients with concomitant coronary heart disease].
Topics: Clinical Trials as Topic; Coronary Disease; Humans; Hypertension; Labetalol; Receptors, Adrenergic, | 1987 |
Beta blockade and intermittent claudication.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Clinical Trials as Topic; Coronary Disease; Female; Gait; | 1985 |
Differential hemodynamic effects of beta-adrenoceptor blockers, Ca antagonists and combined alpha-beta-receptor blockade in ischemic heart disease.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Blood Pressure; Calcium Channel Blockers; | 1986 |
Myocardial ischemia in untreated hypertensive patients: effect of a single small oral dose of a beta-adrenergic blocking agent.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Anesthesia; Atenolol; Clinical Trials as To | 1988 |
Circulatory responses to thiopentone and tracheal intubation in patients with coronary artery disease. Effects of pretreatment with labetalol.
Topics: Anesthesia, General; Blood Pressure; Cardiac Output; Clinical Trials as Topic; Coronary Disease; Dou | 1985 |
20 other studies available for labetalol and Coronary Heart Disease
| Article | Year |
|---|---|
[Demonstration of the beta-blocking effect of labetalol in normotensive coronary patients by means of a hemodynamic study].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Coronary Disease; Ethanolamines; Female; Hemodynamics; Hum | 1981 |
The effects of beta blockers on exercise capacity and on training response in elderly subjects.
Topics: Aged; Atenolol; Coronary Disease; Ethanolamines; Exercise Test; Female; Humans; Hypertension; Labeta | 1984 |
Haemodynamic effects of intravenous labetalol in hypertensive patients with obstructive coronary heart disease complicated by acute myocardial infarction of recent origin.
Topics: Adult; Coronary Disease; Ethanolamines; Exercise Test; Female; Hemodynamics; Humans; Hypertension; I | 1983 |
Antiarrhythmic action of labetalol and its effect on adenine metabolism in the isolated rat heart.
Topics: Adenine; Adenosine Monophosphate; Animals; Anti-Arrhythmia Agents; Coronary Circulation; Coronary Di | 1983 |
I.V. Labetalol during coronary artery surgery.
Topics: Aged; Blood Pressure; Coronary Disease; Ethanolamines; Female; Heart Rate; Hemodynamics; Humans; Inf | 1983 |
[Vasospastic angina pectoris complicated by ventricular fibrillation during treatment with propranolol and labetalol].
Topics: Angina Pectoris, Variant; Coronary Disease; Coronary Vasospasm; Ethanolamines; Female; Humans; Labet | 1983 |
Hemodynamic and coronary effects of intravenous labetalol in coronary artery disease.
Topics: Adult; Blood Pressure; Cardiac Output; Coronary Circulation; Coronary Disease; Ethanolamines; Female | 1982 |
Labetalol: the nineteen-eighties.
Topics: Adrenal Gland Neoplasms; Anesthesia; Coronary Disease; Ethanolamines; Female; Humans; Hypertension; | 1982 |
Influences of labetalol a combined alpha- and beta-adrenergic blocking agent on the dysrhythmias induced by coronary occlusion and reperfusion.
Topics: Animals; Arrhythmias, Cardiac; Cats; Coronary Disease; Disease Models, Animal; Dose-Response Relatio | 1982 |
Norepinephrine release after acute brain death abolishes the cardioprotective effects of ischemic preconditioning in rabbit.
Topics: Animals; Brain Death; Coronary Disease; Disease Models, Animal; Female; Hemodynamics; Ischemic Preco | 2001 |
Acute effects of combined alpha/beta-adrenoceptor blockade v combined beta-receptor and slow channel calcium blockade in ischemic heart disease complicated by hypertension. Hemodynamic and adrenergic responses.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Calcium Channel Blockers; Cardiac Output; | 1991 |
Labetalol and ECT.
Topics: Age Factors; Aged; Coronary Disease; Depressive Disorder; Electroconvulsive Therapy; Humans; Hyperte | 1991 |
Effects of dilevalol in the anesthetized pig with a partially occluded coronary artery.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Anesthesia; Animals; Chloralose; Coronary | 1990 |
Labetalol: time, experience, and adrenergic blockade.
Topics: Coronary Disease; Humans; Hypertension; Intubation, Intratracheal; Labetalol; Postoperative Complica | 1989 |
Vasodilating beta-adrenoceptor blocking drugs do not redistribute myocardial flow during acute coronary ligation in dogs.
Topics: Adrenergic beta-Antagonists; Animals; Coronary Circulation; Coronary Disease; Dogs; Electrocardiogra | 1985 |
The effect of six beta-adrenolytics and labetalol on hepatic biotransformation studied by antipyrine test, in man.
Topics: Adrenergic beta-Antagonists; Adult; Antipyrine; Biotransformation; Coronary Disease; Half-Life; Huma | 1986 |
Systemic and coronary hemodynamics of labetalol in normotensive patients with ischemic heart disease.
Topics: Coronary Circulation; Coronary Disease; Diltiazem; Hemodynamics; Humans; Labetalol; Nicardipine | 1988 |
Systemic and coronary hemodynamic effects of combined oral alpha- and beta-adrenergic blockade (labetalol) in normotensive patients with stable angina pectoris and positive exercise stress tests.
Topics: Administration, Oral; Adult; Aged; Angina Pectoris; Blood Pressure; Coronary Circulation; Coronary D | 1988 |
[Definition and significance of the area at risk in myocardial infarct and the ischemic border zone in acute myocardial infarct].
Topics: Animals; Collateral Circulation; Coronary Circulation; Coronary Disease; Dogs; Electrolytes; Energy | 1986 |
[Intravenous labetalol in normotensive coronary patients. Effects on hemodynamics and myocardial metabolism].
Topics: Adult; Coronary Disease; Energy Metabolism; Ethanolamines; Heart; Hemodynamics; Humans; Injections, | 1985 |